1h Free Analyst Time
The orphan drugs market is forecasted to grow by USD 146.1 billion during 2023-2028, accelerating at a CAGR of 11.62% during the forecast period. The report on the orphan drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by robust pipeline and recent drug approvals, rising incidence of rare diseases, and availability of incentives for orphan drug development.
The orphan drugs market is segmented as below:
By Distribution Channel
- Hospital Pharmacy
- Specialty pharmacy
- Retail pharmacy
- Others
By Product
- Biologics
- Non-biologics
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the orphan drugs market covers the following areas:
- Orphan drugs market sizing
- Orphan drugs market forecast
- Orphan drugs market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Distribution Channel
7 Market Segmentation by Product
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global orphan drugs market: AbbVie Inc., Alnylam Pharmaceuticals Inc., Astellas Pharma Inc., AstraZeneca Plc, bluebird bio Inc., Bristol Myers Squibb Co., CSL Ltd., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Ipsen Pharma, Johnson and Johnson Services Inc., Merck and Co. Inc., Novartis AG, Novo Nordisk AS, Pfizer Inc., Ractigen Therapeutics, Sanofi SA, Takeda Pharmaceutical Co. Ltd., and Vertex Pharmaceuticals Inc..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is strategic focus on alliances, partnerships, and mergers and acquisitions."
According to the report, one of the major drivers for this market is the robust pipeline and recent drug approvals.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Alnylam Pharmaceuticals Inc.
- Astellas Pharma Inc.
- AstraZeneca Plc
- bluebird bio Inc.
- Bristol Myers Squibb Co.
- CSL Ltd.
- F. Hoffmann La Roche Ltd.
- Gilead Sciences Inc.
- GlaxoSmithKline Plc
- Ipsen Pharma
- Johnson and Johnson Services Inc.
- Merck and Co. Inc.
- Novartis AG
- Novo Nordisk AS
- Pfizer Inc.
- Ractigen Therapeutics
- Sanofi SA
- Takeda Pharmaceutical Co. Ltd.
- Vertex Pharmaceuticals Inc.
